CRISPR Gene Editing Market Global Report 2026

The crispr gene editing market size has grown rapidly in recent years. It will grow from $4.03 billion in 2025 to $4.7 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to increasing demand for accurate gene modification technologies, limitations associated with earlier gene editing methods, expansion of genomics research, growing adoption within academic institutions, and increased funding for genetic research.

The crispr gene editing market size is expected to see rapid growth in the next few years. It will grow to $8.61 billion in 2030 at a compound annual growth rate (CAGR) of 16.3%. The growth in the forecast period can be attributed to increasing approvals of gene editing therapies, continued expansion of precision medicine applications, growth of agricultural biotechnology, development of supportive regulatory frameworks, and ongoing technological improvements in CRISPR systems. Major trends in the forecast period include increasing clinical research in gene therapy, expansion of gene editing applications in agriculture, growing adoption of functional genomics research, continued advancements in gene delivery technologies, and increasing emphasis on ethical considerations and regulatory compliance.

The increasing prevalence of genetic disorders is anticipated to support the growth of the CRISPR gene editing market in the coming years. Genetic disorders are medical conditions resulting from abnormalities in the genome, including mutations affecting a single gene (monogenic), several genes (polygenic), or chromosomes. The prevalence of genetic disorders is rising because of genetic mutations, aging populations, and consanguineous marriages. CRISPR gene editing plays an important role in addressing genetic disorders by enabling accurate and targeted changes to DNA. Moreover, researchers utilize CRISPR technology to detect and repair specific mutations responsible for genetic disorders, restore normal biological functions, and reduce disease symptoms, as demonstrated in conditions such as cystic fibrosis and sickle cell anaemia. For instance, in October 2025, according to the Cystic Fibrosis Trust, a UK-based charity focused on supporting individuals affected by cystic fibrosis, 164 new cases of cystic fibrosis (CF) were diagnosed in 2024, of which 123 were detected through newborn screening. At the end of 2024, 11,381 individuals were registered with CF. Therefore, the growing prevalence of genetic disorders is contributing to the expansion of the CRISPR gene editing market.

Key companies operating in the CRISPR gene editing market are focusing on developing innovative products such as gene therapy to reach a larger customer base, increase sales, and enhance revenue. Gene therapy is a medical technique that uses genes to treat, prevent, or cure diseases and disorders. For example, in December 2023, the US Food and Drug Administration (FDA), a US-based federal agency, approved Casgevy, a cell-based gene therapy, for the treatment of sickle cell disease. Casgevy therapy utilizes CRISPR/Cas9, a type of genome editing technology. Hematopoietic stem cells are modified using CRISPR/Cas9 technology.

In April 2024, Cellistic, a Belgium-based cell therapy platform provider, acquired Artisan Bio for an undisclosed amount. Through this acquisition, Cellistic sought to strengthen its gene and cell therapy development capabilities by incorporating Artisan Bio’s STAR-CRISPR Cas-12 gene-editing platform, enabling more precise genome modifications and supporting the development of advanced engineered cell therapy solutions. Artisan Bio is a US-based biotechnology company specializing in next-generation CRISPR gene-editing technologies.

Major companies operating in the crispr gene editing market are Crispr Therapeutics, Thermo Fisher Scientific, Intellia Therapeutics, Horizon Discovery, Synthego Corporation, Integrated DNA Technology (Danaher), Editas Medicine, GenScript, Agilent Technologies, New England Biolabs, CSIR-Institute of Genomics & Integrative Biology (IGIB), Strand Life Sciences Pvt. Ltd., Bio Palette Co. Ltd., Churchi Genome Engineering and Therapeutic Research Center, Beam Therapeutics Inc., Eurofins Genomics India, Setsurotech Co. Ltd., Merck Japan, Institut Pasteur, CureVac, Cellectis, BiovelocITA S.r.l., Evotec A.G., SNIPR Biome, Oxford Genetics, ERS Genomics, Alia Therapeutics, Solvo, BioTalentum, BIOCAD, BioVendor, Research & Diagnostic Products, Contipro, Lonza Biotec, Sotio, Selvita, BioVentures Institute Ltd, Sigma-Aldrich, Poseida Therapeutics, NanoCellect Biomedical, Sherlock Biosciences, Repare Therapeutics, Inscripta Inc., Santa Cruz Biotechnology, Caribou Biosciences Inc., Egenesis Inc., Homology Medicines, System Biosciences, Takara Bio USA Inc., Inari Agriculture Inc., Precision BioSciences, Cell Microsystems Inc., GeneCopoeia Inc., Merck KGaA, Origene Technologies Inc., Pluristem Therapeutics Inc.

North America was the largest region in the CRISPR gene editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr gene editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the crispr gene editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CRISPR gene editing market includes of revenues earned by entities by providing services such as gRNA design and vector construction, cell line and engineering, screening services, drug development services, and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR gene editing market also includes sales of gene editing vectors, laboratory equipment, kits and enzymes, libraries, design tools, antibodies, bioinformatics tools, and cell culture equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

This product will be delivered within 1-3 business days.